Bellevue Medtech & Services (CH)
Medtech & Services is an investment in 10% of global gross domestic product: Healthcare sector excluding drugs
Bottom line: above-average and steady growth compared to the broad market
Focusing on profitable, liquid mid and large cap companies with an established product portfolio
Please find a more detailed description of share classes here.
The Fund invests worldwide in companies active in the medical technology and healthcare services sector. Stock selection is based on fundamental company analysis, focusing in particular on the medical benefits and the potential savings for the healthcare system as well as the expected market potential of a company’s products and services.
Indexed performance (as at: 27.01.2023)
NAV: CHF 3'501.61 (26.01.2023)
Rolling performance (26.01.2023)
|26.01.2022 - 26.01.2023||-0.65%||-1.53%|
|26.01.2021 - 26.01.2022||5.32%||9.94%|
|24.01.2020 - 26.01.2021||7.60%||8.58%|
|25.01.2019 - 24.01.2020||15.96%||20.38%|
Annualized performance (26.01.2023)
|Since Inception p.a.||8.77%||8.49%|
Cumulative performance (26.01.2023)
Facts & Key figures
The Fund invests worldwide in companies active in the medical technology and healthcare services sector. Aim is to provide investors an attractive solution by investing in the entire healthcare universe with the exclusion of drug makers. Experienced sector specialists focus on profitable, liquid mid and large cap companies with an established product portfolio as well as fast growing small cap companies with leading-edge technology offering. Stock selection is based on fundamental company analysis, focusing in particular on the medical benefits and the potential savings for the healthcare system as well as the expected market potential of a company’s products and services.The selection of the portfolio companies is entirely bottom up, independent of benchmark weightings. The Fund takes ESG factors into consideration while implementing the aforementioned investment objectives.Show moreShow less
Investment suitability & Risk
|Investment Manager||Bellevue Asset Management AG|
|Fund Administrator||Swisscanto Fondsleitung AG|
|Auditor||Ernst & Young AG|
|Year end closing||30. Sep|
|NAV Calculation||Daily "Forward Pricing"|
|Cut of time||15:00 CET|
|Subscription Fee (max.)||2.50%|
|Performance Fee||10.00% (with High Water Mark)|
|Legal form||Investment funds under Swiss law|
|SFDR category||Article 8|
Key data (30.12.2022, base currency CHF)
|No. of positions||42|
Top 10 positions
Breakdown by sector
Opportunities & Risks
- Digitalization of the healthcare sector is boosting medtech companies’ growth and earnings.
- Focusing on profitable, liquid mid and large-cap companies with an established product portfolio as well as on rapidly growing small-cap businesses delivering cutting-edge technology.
- Managed care profits from the privatization of the health insurance sector and lower treatment costs.
- Minimally invasive techniques gaining ground – shorter treatment times reduce healthcare costs.
- Bellevue – Healthcare pioneer since 1993 and today one of the biggest independent investors in the sector in Europe.
- The fund invests in equities. Equities are subject to price fluctuations and so are also exposed to the risk of price losses.
- The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The fund may invest in financial instruments that might have a relatively low level of liquidity, which can in turn affect the fund’s liquidity.
- Investing in emerging markets entails the additional risk of political and social instability.
- The fund may engage in derivatives transactions. The increased opportunities gained come with an increased risk of losses.
Review / Outlook
The Bellevue Medtech & Services Fund CH lost ground in December (-5.5%) and closed the month behind its benchmark (-5.0%) and the broad healthcare sector index (-4.2%). Global equities (-7.2%) were much weaker in comparison. Healthcare services had a negative effect of -3.6% on the fund’s performance, medtech stocks -1.9%.
The digital health companies Doximity (-4.3%) and Veeva Systems (-17.9%) detracted from absolute and relative performance. After a strong performance in November (+22.0%), Doximity traded lower on profit-taking. Veeva, a US provider of cloud software solutions, beat sales and earnings expectations for the third quarter, but its weak guidance for the fourth quarter disappointed investors. Veeva management also announced that it would migrate customers from the cloud-based CRM software provided by Salesforce to its own platform called Vault, which caused some uncertainty.
US health insurers Humana (-9.6%), Centene (-8.7%), Elevance (-6.5%), UnitedHealth (-5.9%), Molina (-5.0%) and Cigna (-2.0%) were performance detractors. We attribute their correction to a variety of factors – a severe flu season, the expected normalization of elective procedures in 2023, and the previously strong performance of health insurance stocks going back to mid-June 2022. Their fundamentals, meanwhile, are just as solid as before.
Medtech names Outset Medical (+18.7%), Align Technology (+3.9%), Tandem Diabetes (+3.6%), Zimmer Biomet (+3.1%), Stryker (+1.6%) and Inspire Medical (+1.0%) made positive contributions to absolute performance. Outset Medical, a specialist for digital dialysis management, convinced investors at a conference on its intuitive and convenient hemodialysis system called Tablo, which it claims is the first such system that has a real chance to tap the huge potential that at-home dialysis offers. Tandem Diabetes announced the takeover of AMF Medical. AMF is the developer of Sigi, an insulin patch pump with no tubing, which complements Tandem’s intelligent t:slim X2 insulin pump, which delivers insulin through a tube.
Shockwave (-21.4%), Edwards Lifesciences (-6.4%), Dexcom (-5.6%) and Intuitive Surgical
(-4.9%) hurt the fund's absolute and relative performance. We attribute the lower prices primarily to profit-taking, for example after the FDA approved Dexcom’s new G7 CGM system.
Life science tools companies Danaher (-5.8%) and Thermo Fisher (-4.7%) also had a negative impact on portfolio performance.
All data in CHF unless otherwise stated.
In the healthcare services segment, we believe the US health insurance offer the most upside potential. Premium volumes are expected to show a very good trend in 2023. On the one hand we expect solid enrollment growth in Medicare Advantage and Commercial health plans and above-average premium growth rates on the other. We think the conservative earnings projections of US health insurers offer more than enough cushion to offset a full recovery in elective procedures. What’s more, their minimal forex exposure and the high short to mid-term bond yields can give their earnings an additional boost. On the political front, risks are very low because the US Congress is now divided.
For medtech companies, we expect treatment volumes will be back to normal levels by the end of 2023, given the high levels of immunity and improving staffing conditions at hospitals. Additional upside is certainly possible considering the current treatment backlogs. We assume pricing power will improve, i.e. prices are unlikely to change, whereas during the previous 10 years medtech companies experienced a price erosion of 1-2% p.a. Better cost management and strong sales growth are therefore likely to lead to better margins. Attractive catalysts ranging from new product launches (e.g. TriClip, Dexcom G7, Omnipod 5) and groundbreaking clinical trial results (e.g. TRILUMINATE) to first-time reimbursements (e.g. for CardioMEMS, CGM sensors for type 2 diabetes patients requiring basal insulin therapy) will provide additional upswing.
We think a recession is possible in 2023. Medtech & services stocks tend to outperform in a recessionary environment.
Past performance is not a reliable indicator of future results and can be misleading. As the sub-fund is denominated in a currency that may differ than an investor’s base currency, changes in the rate of exchange may have an adverse effect on prices and incomes. Performance is shown net of fees and expenses for the relevant share class over the reference period. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. Individual costs are not taken into account and would have a negative impact on the performance. With an investment amount of EUR 1,000 over an investment period of five years, the investment result in the first year would be reduced by the front-end load of up to EUR 50 (5%) as well as by additional individual custody charges. In subsequent years, the investment result would also be reduced by the individual custody account costs incurred. The reference benchmark of this class is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to a sub-fund, thus the performance of a benchmark is not a reliable indicator of future performance of the sub-fund it is compared to. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred. All figures in base currency in %, calculated by the total return / BVI method.Show moreShow less